Stock Price
169,600.00
Daily Change
-400.00 -0.24%
Monthly
-1.97%
Yearly
-13.38%
Q3 Forecast
167,529.70

Celltrion reported KRW1.28T in Trade Debtors for its fiscal quarter ending in March of 2025.



Financials
Assets KRW 20958.81B
Cost of Sales KRW 399.04B
Current Assets KRW 5461.18B
Current Liabilities KRW 3403.37B
Debt KRW 2217.55B
EBIT KRW 242.47B
EBITDA KRW 221.03B
Employees 1.07K
Interest Income KRW 7.53B
Loan Capital KRW 114.04B
Market Capitalization KRW 36598.01B
Net Income KRW 108.67B
Operating Expenses KRW 718.99B
Operating Profit KRW 242.47B
Pre-Tax Profit KRW 195.49B
Sales Revenues KRW 961.51B
Stock KRW 2834.03B
Trade Creditors KRW 106.69B
Trade Debtors KRW 1279.99B

Trade Debtors Change Date
Alaunos Therapeutics USD 5K 5K Dec/2024
Avita Medical AUD 11.96M 1.95M Dec/2024
Celltrion KRW 1.28T 205.45B Mar/2025
Dianthus Therapeutics USD 39K 768K Jun/2025
Ionis Pharmaceuticals USD 52.58M 12.87M Jun/2025
IQVIA Holdings USD 3.41B 95M Jun/2025
Moderna USD 457M 151M Jun/2025
Organon & Co USD 1.48B 27M Jun/2025
Revvity USD 661.14M 43.72M Jun/2025
Tectonic Therapeutic USD 0 270K Dec/2023
Viatris USD 3.6B 208.8M Jun/2025
Xeris Pharmaceuticals USD 53.05M 12.64M Jun/2025